Announcements Trials

Browse Landscape

Phase

Phase 1 8 Phase 2 6 Phase EARLY_PHASE1 2 Phase 3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Ovarian Neoplasms 18 Parkinson Disease 4, Autosomal Dominant Lewy Body 6 Breast Neoplasms 6 Metastatic Castration-resistant Prostate Cancer 3 Fallopian Tube Neoplasms 3 Triple Negative Breast Neoplasms 2 Neoplasm Metastasis 2 Endometrial Neoplasms 2 Carcinoma, Ovarian Epithelial 2 Carcinoma 2 Stomach Neoplasms 1 Small Cell Lung Carcinoma 1 Sarcoma 1 Prostatic Neoplasms 1 Peritoneal Neoplasms 1 Pathologic Complete Response 1 Pancreatic Neoplasms 1 Neoplasms 1 Lung Neoplasms 1 Hematologic Neoplasms 1 HER2-ve Metastatic Breast Cancer 1 Colorectal Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Gemcitabine 74 Fluorouracil 31 Oxaliplatin 21 Leucovorin 21 130-nm albumin-bound paclitaxel 17 Capecitabine 14 Irinotecan 12 Albumin-Bound Paclitaxel 10 irinotecan sucrosofate 8 Radiotherapy 6 Taxes 5 Erlotinib Hydrochloride 5 folfirinox 4 rubitecan 3 Surgical Procedures, Operative 3 Specimen Handling 3 Pancreaticojejunostomy 3 Neoadjuvant Therapy 3 Drug Therapy 3 Cisplatin 3 Chemotherapy, Adjuvant 3 ruxolitinib 2 masitinib 2 dehydroftorafur 2 Saline Solution 2 S 1 (combination) 2 Paclitaxel 2 GV1001 peptide 2 Fentanyl 2 Bevacizumab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Pancreatic Neoplasms × olaparib × Clear all

NCT02184195 2023-09-13

POLO

AstraZeneca

Phase 3 Completed

154 enrolled 20 charts 1 FDA

Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡